Impact of GLP-1 Receptor Agonist Therapy on Outcomes in Hidradenitis Suppurativa: A TriNetX Database Study
SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · 3491-3495
DOI: 10.25251/5swch621 ↗Abstract
Background: Hidradenitis Suppurativa is a chronic inflammatory disorder strongly associated with obesity and metabolic dysfunction.1 Glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrate weight-loss and anti-inflammatory effects that may influence postoperative healing.1-3 We evaluated postoperative complications following hidradenitis excision among patients receiving GLP-1RA therapy compared with non-users. Methods: This retrospective cohort study analyzed patients within the TriNetX database, aggregating electronic medical records and claims data from 70 healthcare organizations representing over 101 million patients. Included patients underwent hidradenitis excision involving the axillary (CPT-11450, CPT-11451), perianal/perineal/umbilical (CPT-11470, CPT-11471), or inguinal regions (CPT-11462, CPT-11463). Cohorts were stratified by preoperative GLP-1RA use, including Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, or Exenatide, prescribed up to one day prior to surgery. One-to-one propensity score matching was performed for age, sex, race, ethnicity, comorbidities, HS-related procedures, and immunosuppressive therapy. Outcomes assessed at 1 and 3 months postoperatively included infection, debridement, reoperation, wound dehiscence, sepsis, thromboembolic events, emergency department visits, and overall complications. Reoperation was defined as repeat hidradenitis excision occurring ≥1 day after index surgery. Results: After propensity score matching, 2,992 patients were included (1,496 per cohort), with balanced baseline characteristics (standardized mean differences
EUVIMED